OBJECTIVE: To determine the safety and efficacy of liposomal amphotericin B (AmBisome) in the primary treatment of AIDS-associated cryptococcosis. DESIGN: A Phase II, multicentre, European, non-comparative, open study to assess the use of AmBisome in 23 patients (26 enrolments) with cryptococcosis. Dose requirements, mycological response and toxicity were documented. SETTING: Hospital-based HIV units. PATIENTS: Twenty-three HIV-1-seropositive patients. RESULTS: Drug toxicity, assessed in 25 enrolments, was well-tolerated with little renal, hepatic or haematological toxicity. Eighteen out of 23 (78%) enrolments responded clinically. Nineteen enrolments had cryptococcal meningitis: sterilization of spinal fluid was achieved in 12 out of the 18 (67%) who were mycologically evaluable. Fourteen out of the 19 (74%) responded clinically. CONCLUSION: AmBisome is well-tolerated and may be an effective formulation in the treatment of cryptococcosis.
OBJECTIVE: To determine the safety and efficacy of liposomal amphotericin B (AmBisome) in the primary treatment of AIDS-associated cryptococcosis. DESIGN: A Phase II, multicentre, European, non-comparative, open study to assess the use of AmBisome in 23 patients (26 enrolments) with cryptococcosis. Dose requirements, mycological response and toxicity were documented. SETTING: Hospital-based HIV units. PATIENTS: Twenty-three HIV-1-seropositivepatients. RESULTS:Drug toxicity, assessed in 25 enrolments, was well-tolerated with little renal, hepatic or haematological toxicity. Eighteen out of 23 (78%) enrolments responded clinically. Nineteen enrolments had cryptococcal meningitis: sterilization of spinal fluid was achieved in 12 out of the 18 (67%) who were mycologically evaluable. Fourteen out of the 19 (74%) responded clinically. CONCLUSION:AmBisome is well-tolerated and may be an effective formulation in the treatment of cryptococcosis.
Authors: Chrissy M Leopold Wager; Camaron R Hole; Karen L Wozniak; Michal A Olszewski; Mathias Mueller; Floyd L Wormley Journal: Infect Immun Date: 2015-09-08 Impact factor: 3.441
Authors: Karl V Clemons; Raymond A Sobel; Paul L Williams; Demosthenes Pappagianis; David A Stevens Journal: Antimicrob Agents Chemother Date: 2002-08 Impact factor: 5.191
Authors: M A Viviani; G Rizzardini; A M Tortorano; M Fasan; A Capetti; A M Roverselli; A Gringeri; F Suter Journal: Infection Date: 1994 Mar-Apr Impact factor: 3.553